Skeletal and extraskeletal actions of denosumab

Endocrine

Volumn 42, Issue 1, 2012, Pages 52-62

  Sinningen, Kathrin ^a   Tsourdi, Elena ^a   Rauner, Martina ^a   Rachner, Tilman D ^a   Hamann, Christine ^a   Hofbauer, Lorenz C ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

Bone metastases; Denosumab; OPG; Osteoporosis; RANK; RANKL

Indexed keywords

ALENDRONIC ACID; ANDROGEN; ANTIANDROGEN; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; GLUCOCORTICOID; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ZOLEDRONIC ACID;

ANDROGEN THERAPY; ARTERY CALCIFICATION; BONE METASTASIS; BONE REMODELING; BONE STRENGTH; BREAST CANCER; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; HYPERCALCEMIA; IMMUNE SYSTEM; IMMUNOREGULATION; INFLAMMATORY DISEASE; NONHUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SKELETON; THERMOREGULATION; UNSPECIFIED SIDE EFFECT;

EID: 84865034614     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9696-x     Document Type: Review

References (135)

1. H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, N. Udagawa, N. Takahashi, T. Suda, Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95, 3597-3602 (1998)
2. L.C. Hofbauer, A.E. Heufelder, Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J. Clin. Endocrinol. Metab. 85, 2355-2363 (2000)
3. P. Collin-Osdoby, Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ. Res. 95, 1046-1057 (2004)
4. G. Silvestrini, P. Ballanti, F. Patacchioli, M. Leopizzi, N. Gualtieri, P. Monnazzi, E. Tremante, D. Sardella, E. Bonucci, Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. J. Mol. Histol. 36, 59-67 (2005)
5. T. Nakashima, M. Hayashi, T. Fukunaga, K. Kurata, M. Oh-Hora, J.Q. Feng, L.F. Bonewald, T. Kodama, A. Wutz, E.F. Wagner, J.M. Penninger, H. Takayanagi, Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231-1234 (2011)
6. H. Hsu, D.L. Lacey, C.R. Dunstan, I. Solovyev, A. Colombero, E. Timms, H.L. Tan, G. Elliott, M.J. Kelley, I. Sarosi, L. Wang, X.Z. Xia, R. Elliott, L. Chiu, T. Black, S. Scully, C. Capparelli, S. Morony, G. Shimamoto, M.B. Bass, W.J. Boyle, Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl Acad. Sci. USA 96, 3540-3545 (1999)
7. J.-K. Min, Y.-M. Kim, Y.-M. Kim, E.-C. Kim, Y.S. Gho, I.-J. Kang, S.-Y. Lee, Y.-Y. Kong, Y.-G. Kwon, Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J. Biol. Chem. 278, 39548-39557 (2003)
8. S. Panizo, A. Cardus, M. Encinas, E. Parisi, P. Valcheva, S. López-Ongil, B. Coll, E. Fernandez, J.M. Valdivielso, RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ. Res. 104, 1041-1048 (2009)
9. D. Santini, G. Schiavon, B. Vincenzi, L. Gaeta, F. Pantano, A. Russo, C. Ortega, C. Porta, S. Galluzzo, G. Armento, N. La Verde, C. Caroti, I. Treilleux, A. Ruggiero, G. Perrone, R. Addeo, P. Clezardin, A.O. Muda, G. Tonini, Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS ONE 6, e19234 (2011)
10. W.C. Dougall, M. Glaccum, K. Charrier, K. Rohrbach, K. Brasel, T. De Smedt, E. Daro, J. Smith, M.E. Tometsko, C.R. Maliszewski, A. Armstrong, V. Shen, S. Bain, D. Cosman, D. Anderson, P.J. Morrissey, J.J. Peschon, J. Schuh, RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2424 (1999)
11. Y.Y. Kong, H. Yoshida, I. Sarosi, H.L. Tan, E. Timms, C. Capparelli, S. Morony, A.J. Oliveira-dos-Santos, G. Van, A. Itie, W. Khoo, A. Wakeham, C.R. Dunstan, D.L. Lacey, T.W. Mak, W.J. Boyle, J.M. Penninger, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999)
12. J.E. Fata, Y.Y. Kong, J. Li, T. Sasaki, J. Irie-Sasaki, R.A. Moorehead, R. Elliott, S. Scully, E.B. Voura, D.L. Lacey, W.J. Boyle, R. Khokha, J.M. Penninger, The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41-50 (2000)
13. L.C. Hofbauer, A.E. Heufelder, Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J. Mol. Med. 79, 243-253 (2001)
14. W.S. Simonet, D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, R. Lüthy, H.Q. Nguyen, S. Wooden, L. Bennett, T. Boone, G. Shimamoto, M. DeRose, R. Elliott, A. Colombero, H.L. Tan, G. Trail, J. Sullivan, E. Davy, N. Bucay, L. Renshaw-Gegg, T.M. Hughes, D. Hill, W. Pattison, P. Campbell, S. Sander, G. Van, J. Tarpley, P. Derby, R. Lee, W.J. Boyle, Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997)
15. T.L. Burgess, Y. Qian, S. Kaufman, B.D. Ring, G. Van, C. Capparelli, M. Kelley, H. Hsu, W.J. Boyle, C.R. Dunstan, S. Hu, D.L. Lacey, The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145, 527-538 (1999)
16. D.L. Lacey, H.L. Tan, J. Lu, S. Kaufman, G. Van, W. Qiu, A. Rattan, S. Scully, F. Fletcher, T. Juan, M. Kelley, T.L. Burgess, W.J. Boyle, A.J. Polverino, Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 157, 435-448 (2000)
17. G. Eghbali-Fatourechi, S. Khosla, A. Sanyal, W.J. Boyle, D.L. Lacey, B.L. Riggs, Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 111, 1221-1230 (2003)
18. C. von Tirpitz, S. Epp, J. Klaus, R. Mason, G. Hawa, N. Brinskelle-Schmal, L.C. Hofbauer, G. Adler, W. Kratzer, M. Reinshagen, Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur. J. Gastroenterol. 15, 1165-1170 (2003)
19. H. Mori, R. Kitazawa, S. Mizuki, M. Nose, S. Maeda, S. Kitazawa, RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. Histochem. Cell Biol. 117, 283-292 (2002)
20. T. Standal, C. Seidel, Ø. Hjertner, T. Plesner, R.D. Sanderson, A. Waage, M. Borset, A. Sundan, Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100, 3002-3007 (2002)
21. T. Michigami, M. Ihara-Watanabe, M. Yamazaki, K. Ozono, Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res. 61, 1637-1644 (2001)
22. W. Lieb, P. Gona, M.G. Larson, J.M. Massaro, I. Lipinska, J.F. Keaney, J. Rong, D. Corey, U. Hoffmann, C.S. Fox, R.S. Vasan, E.J. Benjamin, C.J. O'Donnell, S. Kathiresan, Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler. Thromb. Vasc. Biol. 30, 1849-1854 (2010)
23. J.-J. Body, P. Greipp, R.E. Coleman, T. Facon, F. Geurs, J.-P. Fermand, J.-L. Harousseau, A. Lipton, X. Mariette, C.D. Williams, A. Nakanishi, D. Holloway, S.W. Martin, C.R. Dunstan, P.J. Bekker, A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97, 887-892 (2003)
24. L.M. Weiner, Fully human therapeutic monoclonal antibodies. J. Immunother. 29, 1-9 (1997)
25. P.J. Kostenuik, Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr. Opin. Pharmacol. 5, 618-625 (2005)
26. Y.Y. Yuan, P.J. Kostenuik, M.S. Ominsky, S. Morony, S. Adamu, D.T. Simionescu, D.M. Basalyga, F.J. Asuncion, T.A. Bateman, Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. Osteoporos. Int. 19, 625-635 (2008)
27. S.A.J. Lloyd, Y.Y. Yuan, P.J. Kostenuik, M.S. Ominsky, A.G. Lau, S. Morony, M. Stolina, F.J. Asuncion, T.A. Bateman, Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. Calcif. Tissue Int. 82, 361-372 (2008)
28. S. Kwan Tat, M. Padrines, S. Théoleyre, D. Heymann, Y. Fortun, IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 15, 49-60 (2004)
29. C. Capparelli, S. Morony, K. Warmington, S. Adamu, D. Lacey, C.R. Dunstan, B. Stouch, S. Martin, P.J. Kostenuik, Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J. Bone Miner. Res. 18, 852-858 (2003)
30. M.S. Ominsky, P.J. Kostenuik, P. Cranmer, S.Y. Smith, J.E. Atkinson, The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Osteoporos. Int. 18, 1073-1082 (2007)
31. T. Yoneda, N. Ishimaru, R. Arakaki, M. Kobayashi, T. Izawa, K. Moriyama, Y. Hayashi, Estrogen deficiency accelerates murine autoimmune arthritis associated with receptor activator of nuclear factor-kappa B ligand-mediated osteoclastogenesis. Endocrinology 145, 2384-2391 (2004)
32. T. Miyazaki, T. Matsunaga, S. Miyazaki, S. Hokari, T. Komoda, Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. J. Cell. Biochem. 93, 503-512 (2004)
33. F.-S. Wang, J.-Y. Ko, C.-L. Lin, H.-L. Wu, H.-J. Ke, P.-J. Tai, Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone 40, 485-492 (2007)
34. T. Ikeda, M. Utsuyama, K. Hirokawa, Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J. Bone Miner. Res. 16, 1416-1425 (2001)
35. M.S. Ominsky, X. Li, F.J. Asuncion, M. Barrero, K.S. Warmington, D. Dwyer, M. Stolina, Z. Geng, M. Grisanti, H.-L. Tan, T. Corbin, J. McCabe, W.S. Simonet, H.Z. Ke, P.J. Kostenuik, RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J. Bone Miner. Res. 23, 672-682 (2008)
36. M. Gunness, E. Orwoll, Early induction of alterations in cancellous and cortical bone histology after orchiectomy in mature rats. J. Bone Miner. Res. 10, 1735-1744 (1995)
37. R.S. Weinstein, R.L. Jilka, A.M. Parfitt, S.C. Manolagas, The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage. Endocrinology 138, 4013-4021 (1997)
38. D.M. Huber, A.C. Bendixen, P. Pathrose, S. Srivastava, K.M. Dienger, N.K. Shevde, J.W. Pike, Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 142, 3800-3808 (2001)
39. L. Pederson, M. Kremer, J. Judd, D. Pascoe, T.C. Spelsberg, B.L. Riggs, M.J. Oursler, Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc. Natl Acad. Sci. USA 96, 505-510 (1999)
40. Q. Chen, H. Kaji, M. Kanatani, T. Sugimoto, K. Chihara, Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. Horm. Metab. Res. 36, 674-678 (2004)
41. L.C. Hofbauer, K.C. Hicok, D. Chen, S. Khosla, Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. Eur. J. Endocrinol. 147, 269-273 (2002)
42. V. Proell, H. Xu, C. Schüler, K. Weber, L.C. Hofbauer, R.G. Erben, Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats. Bone 45, 677-681 (2009)
43. X. Li, M.S. Ominsky, M. Stolina, K.S. Warmington, Z. Geng, Q.-T. Niu, F.J. Asuncion, H.-L. Tan, M. Grisanti, D. Dwyer, S. Adamu, H.Z. Ke, W.S. Simonet, P.J. Kostenuik, Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone 45, 669-676 (2009)
44. R.T. Turner, G.K. Wakley, K.S. Hannon, Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J. Orthop. Res. 8, 612-617 (1990)
45. E. Romas, O. Bakharevski, D.K. Hards, V. Kartsogiannis, J.M. Quinn, P.F. Ryan, T.J. Martin, M.T. Gillespie, Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 43, 821-826 (2000)
46. M. Stolina, S. Adamu, M. Ominsky, D. Dwyer, F. Asuncion, Z. Geng, S. Middleton, H. Brown, J. Pretorius, G. Schett, B. Bolon, U. Feige, D. Zack, P.J. Kostenuik, RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J. Bone Miner. Res. 20, 1756-1765 (2005)
47. Y.Y. Kong, U. Feige, I. Sarosi, B. Bolon, A. Tafuri, S. Morony, C. Capparelli, J. Li, R. Elliott, S. McCabe, T. Wong, G. Campagnuolo, E. Moran, E.R. Bogoch, G. Van, L.T. Nguyen, P.S. Ohashi, D.L. Lacey, E. Fish, W.J. Boyle, J.M. Penninger, Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304-309 (1999)
48. M. Stolina, B. Bolon, S. Middleton, D. Dwyer, H. Brown, D. Duryea, L. Zhu, A. Rohner, J. Pretorius, P. Kostenuik, U. Feige, D. Zack, The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. J. Clin. Immunol. 29, 158-174 (2009)
49. B. Bolon, G. Campagnuolo, U. Feige, Duration of bone protection by a single osteoprotegerin injection in rats with adjuvantinduced arthritis. Cell. Mol. Life Sci. 59, 1569-1576 (2002)
50. M. Stolina, G. Schett, D. Dwyer, S. Vonderfecht, S. Middleton, D. Duryea, E. Pacheco, G. Van, B. Bolon, U. Feige, D. Zack, P. Kostenuik, RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Res. Ther. 11, R187 (2009)
51. G. Schett, S. Middleton, B. Bolon, M. Stolina, H. Brown, L. Zhu, J. Pretorius, D.J. Zack, P. Kostenuik, U. Feige, Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum. 52, 1604-1611 (2005)
52. K. Redlich, B. Görtz, S. Hayer, J. Zwerina, N. Doerr, P. Kostenuik, H. Bergmeister, G. Kollias, G. Steiner, J.S. Smolen, G. Schett, Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am. J. Pathol. 164, 543-555 (2004)
53. N. Saidenberg-Kermanac'h, A. Corrado, D. Lemeiter, M.C. deVernejoul, M.C. Boissier, M.E. Cohen-Solal, TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35, 1200-1207 (2004)
54. E. Romas, N.A. Sims, D.K. Hards, M. Lindsay, J.W.M. Quinn, P.F.J. Ryan, C.R. Dunstan, T.J. Martin, M.T. Gillespie, Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am. J. Pathol. 161, 1419-1427 (2002)
55. R.S. Weinstein, Clinical practice. Glucocorticoid-induced bone disease. N. Engl. J. Med. 365, 62-70 (2011)
56. N.O. Vidal, H. Brändström, K.B. Jonsson, C. Ohlsson, Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J. Endocrinol. 159, 191-195 (1998)
57. L.C. Hofbauer, F. Gori, B.L. Riggs, D.L. Lacey, C.R. Dunstan, T.C. Spelsberg, S. Khosla, Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140, 4382-4389 (1999)
58. R.S. Weinstein, R.L. Jilka, A.M. Parfitt, S.C. Manolagas, Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102, 274-282 (1998)
59. S. Ikeda, Y. Morishita, H. Tsutsumi, M. Ito, A. Shiraishi, S. Arita, S. Akahoshi, K. Narusawa, T. Nakamura, Reductions in bone turnover, mineral, and structure associated with mechanical properties of lumbar vertebra and femur in glucocorticoidtreated growing minipigs. Bone 33, 779-787 (2003)
60. P. Oelzner, S. Fleissner-Richter, R. Bräuer, G. Hein, G. Wolf, T. Neumann, Combination therapy with dexamethasone and osteoprotegerin protects against arthritis-induced bone alterations in antigen-induced arthritis of the rat. Inflamm. Res. 59, 731-741 (2010)
61. P.J. Bekker, D.L. Holloway, A.S. Rasmussen, R. Murphy, S.W. Martin, P.T. Leese, G.B. Holmes, C.R. Dunstan, A.M. DePaoli, A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059-1066 (2004)
62. M.R. McClung, E.M. Lewiecki, S.B. Cohen, M.A. Bolognese, G.C. Woodson, A.H. Moffett, M. Peacock, P.D. Miller, S.N. Lederman, C.H. Chesnut, D. Lain, A.J. Kivitz, D.L. Holloway, C. Zhang, M.C. Peterson, P.J. Bekker, Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354, 821-831 (2006)
63. E.M. Lewiecki, P.D. Miller, M.R. McClung, S.B. Cohen, M.A. Bolognese, Y. Liu, A. Wang, S. Siddhanti, L.A. Fitzpatrick, A.M.G. Bone, L. Study, Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with lowBMD. J. Bone Miner. Res. 22, 1832-1841 (2007)
64. P.D. Miller, M.A. Bolognese, E.M. Lewiecki, M.R. McClung, B. Ding, M. Austin, Y. Liu, J. San Martin, Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43, 222-229 (2008)
65. P.D. Miller, R.B. Wagman, M. Peacock, E.M. Lewiecki, M.A. Bolognese, R.L. Weinstein, B. Ding, J. San Martin, M.R. McClung, Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J. Clin. Endocrinol. Metab. 96, 394-402 (2011)
66. S. Boonen, S. Ferrari, P.D. Miller, E.F. Eriksen, P.N. Sambrook, J. Compston, I.R. Reid, D. Vanderschueren, F. Cosman, Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective. J. Bone Miner. Res. 27(5), 963-974 (2012)
67. G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58-69 (2012)
68. J. Compston, The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine 41(1), 11-18 (2012)
69. T.D. Rachner, S. Khosla, L.C. Hofbauer, Osteoporosis: now and the future. Lancet 377(9773), 1276-1287 (2011)
70. S.R. Cummings, J. San Martin, M.R. McClung, E.S. Siris, R. Eastell, I.R. Reid, P. Delmas, H.B. Zoog, M. Austin, A. Wang, S. Kutilek, S. Adami, J. Zanchetta, C. Libanati, S. Siddhanti, C. Christiansen, Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756-765 (2009)
71. ®. J. Bone Miner. Res. (2012). doi:10.1002/jbmr.1606
72. J.P. Brown, R.L. Prince, C. Deal, R.R. Recker, D.P. Kiel, L.H. de Gregorio, P. Hadji, L.C. Hofbauer, J.M. Alvaro-Gracia, H. Wang, M. Austin, R.B. Wagman, R. Newmark, C. Libanati, J. San Martin, H.G. Bone, Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J. Bone Miner. Res. 24(1), 153-161 (2009)
73. S. Papapoulos, R. Chapurlat, C. Libanati, M. Brandi, J. Brown, E. Czerwiński, M.A. Krieg, Z. Man, D. Mellström, S. Radominski, J.Y. Reginster, H. Resch, J. Román, C. Roux, E. Vittinghoff, M. Austin, N. Daizadeh, M. Bradley, A. Grauer, S. Cummings, H. Bone, Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J. Bone Miner. Res. 27(3), 694-701 (2011)
74. N. Freemantle, S. Satram-Hoang, E.-T. Tang, P. Kaur, D. Macarios, S. Siddhanti, J. Borenstein, D.L. Kendler, Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos. Int. 23(1), 317-326 (2012)
75. R.E. Coleman, Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12, 6243s-6249s (2006)
76. J. Zekri, N. Ahmed, R.E. Coleman, B.W. Hancock, The skeletal metastatic complications of renal cell carcinoma. Int. J. Oncol. 19, 379-382 (2001)
77. Y. Wittrant, S. Théoleyre, C. Chipoy, M. Padrines, F. Blanchard, D. Heymann, F. Rédini, RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim. Biophys. Acta 1704, 49-57 (2004)
78. Bendre, M., Gaddy, D., Nicholas, R.W., Suva, L.J.: Breast cancer metastasis to bone: it is not all about PTHrP. Clin. Orthop. Relat. Res. (415 Suppl) S39-45 (2003)
79. R.J. Thomas, T.A. Guise, J.J. Yin, J. Elliott, N.J. Horwood, T.J. Martin, M.T. Gillespie, Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140, 4451-4458 (1999)
80. J.M. Brown, E. Corey, Z.D. Lee, L.D. True, T.J. Yun, M. Tondravi, R.L. Vessella, Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57, 611-616 (2001)
81. O. Sezer, U. Heider, I. Zavrski, C.A. Kühne, L.C. Hofbauer, RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101, 2094-2098 (2003)
82. S. Yaccoby, M.J. Wezeman, A. Henderson, M. Cottler-Fox, Q. Yi, B. Barlogie, J. Epstein, Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 64, 2016-2023 (2004)
83. N. Giuliani, R. Bataille, C. Mancini, M. Lazzaretti, S. Barillé, Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98, 3527-3533 (2001)
84. R.N. Pearse, E.M. Sordillo, S. Yaccoby, B.R. Wong, D.F. Liau, N. Colman, J. Michaeli, J. Epstein, Y. Choi, Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl Acad. Sci. USA 98, 11581-11586 (2001)
85. T. Okada, S. Akikusa, H. Okuno, M. Kodaka, Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. Clin. Exp. Metastasis 20, 639-646 (2003)
86. C.M. Shipman, P.I. Croucher, Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosisinducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63, 912-916 (2003)
87. J.R. Canon, M. Roudier, R. Bryant, S. Morony, M. Stolina, P.J. Kostenuik, W.C. Dougall, Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin. Exp. Metastasis 25, 119-129 (2008)
88. S. Mikami, K. Katsube, M. Oya, M. Ishida, T. Kosaka, R. Mizuno, S. Mochizuki, T. Ikeda, M. Mukai, Y. Okada, Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J. Pathol. 218(4), 530-539 (2009)
89. D.H. Jones, T. Nakashima, O.H. Sanchez, I. Kozieradzki, S.V. Komarova, I. Sarosi, S. Morony, E. Rubin, R. Sarao, C.V. Hojilla, V. Komnenovic, Y.-Y. Kong, M. Schreiber, S.J. Dixon, S.M. Sims, R. Khokha, T. Wada, J.M. Penninger, Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692-696 (2006)
90. H. Yonou, N. Kanomata, M. Goya, T. Kamijo, T. Yokose, T. Hasebe, K. Nagai, T. Hatano, Y. Ogawa, A. Ochiai, Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 63, 2096-2102 (2003)
91. R.E. Miller, M. Roudier, J. Jones, A. Armstrong, J. Canon, W.C. Dougall, RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol. Cancer Ther. 7, 2160-2169 (2008)
92. J. Zhang, J. Dai, Y. Qi, D.L. Lin, P. Smith, C. Strayhorn, A. Mizokami, Z. Fu, J. Westman, E.T. Keller, Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107, 1235-1244 (2001)
93. S. Morony, K. Warmington, S. Adamu, F. Asuncion, Z. Geng, M. Grisanti, H.L. Tan, C. Capparelli, C. Starnes, B. Weimann, C.R. Dunstan, P.J. Kostenuik, The inhibition ofRANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 146, 3235-3243 (2005)
94. G.K. Ellis, H.G. Bone, R. Chlebowski, D. Paul, S. Spadafora, J. Smith, M. Fan, S. Jun, Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 26, 4875-4882 (2008)
95. M.R. Smith, B. Egerdie, N. Hernández Toriz, R. Feldman, T.L.J. Tammela, F. Saad, J. Heracek, M. Szwedowski, C. Ke, A. Kupic, B.Z. Leder, C. Goessl, Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745-755 (2009)
96. K. Fizazi, M. Carducci, M. Smith, R. Damião, J. Brown, L. Karsh, P. Milecki, N. Shore, M. Rader, H. Wang, Q. Jiang, S. Tadros, R. Dansey, C. Goessl, Denosumab versus zoledronic acid for treatment of bone metastases in men with castrationresistant prostate cancer: a randomised, double-blind study. Lancet 377, 813-822 (2011)
97. M.R. Smith, F. Saad, R. Coleman, N. Shore, K. Fizazi, B. Tombal, K. Miller, P. Sieber, L. Karsh, R. Damião, T.L. Tammela, B. Egerdie, H. Van Poppel, J. Chin, J. Morote, F. Gómez-Veiga, T. Borkowski, Z. Ye, A. Kupic, R. Dansey, C. Goessl, Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379, 39-46 (2011)
98. A.T. Stopeck, A. Lipton, J.-J. Body, G.G. Steger, K. Tonkin, R.H. de Boer, M. Lichinitser, Y. Fujiwara, D.A. Yardley, M. Viniegra, M. Fan, Q. Jiang, R. Dansey, S. Jun, A. Braun, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132-5139 (2010)
99. D.H. Henry, L. Costa, F. Goldwasser, V. Hirsh, V. Hungria, J. Prausova, G.V. Scagliotti, H. Sleeboom, A. Spencer, S. Vadhan-Raj, R. von Moos, W. Willenbacher, P.J. Woll, J. Wang, Q. Jiang, S. Jun, R. Dansey, H. Yeh, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125-1132 (2011)
100. D.P. Kiel, L.I. Kauppila, L.A. Cupples, M.T. Hannan, C.J. O'Donnell, P.W. Wilson, Bone loss and the progression of abdominal aortic calcification over a 25 year period: The Framingham Heart Study, New York. Calcif. Tissue Int. 74(2), 208 (2001)
101. M. Baud'huin, F. Lamoureux, L. Duplomb, F. Rédini, D. Heymann, RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell. Mol. Life Sci. 64, 2334-2350 (2007)
102. N. Bucay, I. Sarosi, C.R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H.L. Tan, W. Xu, D.L. Lacey, W.J. Boyle, W.S. Simonet, Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268 (1998)
103. H. Min, S. Morony, I. Sarosi, C.R. Dunstan, C. Capparelli, S. Scully, G. Van, S. Kaufman, P.J. Kostenuik, D.L. Lacey, W.J. Boyle, W.S. Simonet, Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J. Exp. Med. 192, 463-474 (2000)
104. S. Morony, Y. Tintut, Z. Zhang, R.C. Cattley, G. Van, D. Dwyer, M. Stolina, P.J. Kostenuik, L.L. Demer, Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 117, 411-420 (2008)
105. M.K. Osako, H. Nakagami, N. Koibuchi, H. Shimizu, F. Nakagami, H. Koriyama, M. Shimamura, T. Miyake, H. Rakugi, R. Morishita, Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ. Res. 107, 466-475 (2010)
106. S. Helas, C. Goettsch, M. Schoppet, U. Zeitz, U. Hempel, H. Morawietz, P.J. Kostenuik, R.G. Erben, L.C. Hofbauer, Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am. J. Pathol. 175, 473-478 (2009)
107. G.G. Teng, N.M. Patkar, K.G. Saag, Denosumab in postmenopausal women with low bone mineral density. Curr. Rheumatol. Rep. 9(1), 48-49 (2007)
108. A. Lipton, G.G. Steger, J. Figueroa, C. Alvarado, P. Solal-Celigny, J.-J. Body, R. de Boer, R. Berardi, P. Gascon, K.S. Tonkin, R. Coleman, A.H.G. Paterson, M.C. Peterson, M. Fan, A. Kinsey, S. Jun, Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancerrelated bone metastases. J. Clin. Oncol. 25, 4431-4437 (2007)
109. M.J. Green, A.A. Deodhar, Bone changes in early rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 15, 105-123 (2001)
110. G. Kaya, E. Koçak, E. Akbal, A. Taş, S. Köklü, Comparison of the possible risk factors of bone mineral density in subjects with ulcerative colitis and healthy subjects. South. Med. J. 104, 747-751 (2011)
111. L. Graat-Verboom, F.W. Smeenk, B.E. van den Borne, M.A. Spruit, F.H. Jansen, J.W. van Enschot, E.F. Wouters, Progression of osteoporosis in patients with COPD: a 3-year follow up study. Respir. Med. 106(6), 861-870 (2012)
112. D. Carmona-Fernandes, M.J. Santos, I.P. Perpétuo, J.E. Fonseca, H. Canhão, Soluble receptor activator of nuclear factor jB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients. Arthritis Res. Ther. 13, R175 (2011)
113. H. Takayanagi, H. Iizuka, T. Juji, T. Nakagawa, A. Yamamoto, T. Miyazaki, Y. Koshihara, H. Oda, K. Nakamura, S. Tanaka, Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 43, 259-269 (2000)
114. Y. Li, G. Toraldo, A. Li, X. Yang, H. Zhang, W.-P. Qian, M.N. Weitzmann, B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109, 3839-3848 (2007)
115. S. Cenci, G. Toraldo, M.N. Weitzmann, C. Roggia, Y. Gao, W.P. Qian, O. Sierra, R. Pacifici, Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc. Natl Acad. Sci. USA 100, 10405-10410 (2003)
116. D.M. Anderson, E. Maraskovsky, W.L. Billingsley, W.C. Dougall, M.E. Tometsko, E.R. Roux, M.C. Teepe, R.F. DuBose, D. Cosman, L. Galibert, A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179 (1997)
117. P. Bai, Y. Sun, J. Jin, J. Hou, R. Li, Q. Zhang, Y. Wang, Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respir. Res. 12, 157 (2011)
118. R.L. Van Bezooijen, H.C. Farih-Sips, S.E. Papapoulos, C.W. Löwik, Interleukin-17: a new bone acting cytokine in vitro. J. Bone Miner. Res. 14, 1513-1521 (1999)
119. E. Lubberts, L. van den Bersselaar, B. Oppers-Walgreen, P. Schwarzenberger, C.J. Coenen-de Roo, J.K. Kolls, L.A. Joosten, W.B. van den Berg, IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J. Immunol. 170(5), 2655-2662 (2003)
120. G. Schett, K. Redlich, S. Hayer, J. Zwerina, B. Bolon, C. Dunstan, B. Görtz, A. Schulz, H. Bergmeister, G. Kollias, G. Steiner, J.S. Smolen, Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum. 48, 2042-2051 (2003)
121. A.R. Pettit, H. Ji, D. von Stechow, R. Mü ller, S.R. Goldring, Y. Choi, C. Benoist, E.M. Gravallese, TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 159, 1689-1699 (2001)
122. A.J. Ashcroft, S.M. Cruickshank, P.I. Croucher, M.J. Perry, S. Rollinson, J.M. Lippitt, J.A. Child, C. Dunstan, P.J. Felsburg, G.J. Morgan, S.R. Carding, Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 19, 849-861 (2003)
123. S.B. Cohen, R.K. Dore, N.E. Lane, P.A. Ory, C.G. Peterfy, J.T. Sharp, D. van der Heijde, L. Zhou, W. Tsuji, R. Newmark, Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelvemonth, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 58, 1299-1309 (2008)
124. J.T. Sharp, W. Tsuji, P. Ory, C. Harper-Barek, H. Wang, R. Newmark, Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res. 62, 537-544 (2010)
125. A. Deodhar, R.K. Dore, D. Mandel, J. Schechtman, W. Shergy, R. Trapp, P.A. Ory, C.G. Peterfy, T. Fuerst, H. Wang, L. Zhou, W. Tsuji, R. Newmark, Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res. 62, 569-574 (2010)
126. D. Kim, R.E. Mebius, J.D. MacMicking, S. Jung, T. Cupedo, Y. Castellanos, J. Rho, B.R. Wong, R. Josien, N. Kim, P.D. Rennert, Y. Choi, Regulation of peripheral lymph node genesis by the tumor necrosis factor family member trance. J. Exp. Med. 192, 1467-1478 (2000)
127. Y. Hikosaka, T. Nitta, I. Ohigashi, K. Yano, N. Ishimaru, Y. Hayashi, M. Matsumoto, K. Matsuo, J.M. Penninger, H. Takayanagi, Y. Yokota, H. Yamada, Y. Yoshikai, J.-I. Inoue, T. Akiyama, Y. Takahama, The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 29, 438-450 (2008)
128. M.M. Guerrini, C. Sobacchi, B. Cassani, M. Abinun, S.S. Kilic, A. Pangrazio, D. Moratto, E. Mazzolari, J. Clayton-Smith, P. Orchard, F.P. Coxon, M.H. Helfrich, J.C. Crockett, D. Mellis, A. Vellodi, I. Tezcan, L.D. Notarangelo, M.J. Rogers, P. Vezzoni, A. Villa, A. Frattini, Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am. J. Hum. Genet. 83, 64-76 (2008)
129. C. Sobacchi, A. Frattini, M.M. Guerrini, M. Abinun, A. Pangrazio, L. Susani, R. Bredius, G. Mancini, A. Cant, N. Bishop, P. Grabowski, A. Del Fattore, C. Messina, G. Errigo, F.P. Coxon, D.I. Scott, A. Teti, M.J. Rogers, P. Vezzoni, A. Villa, M.H. Helfrich, Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat. Genet. 39, 960-962 (2007)
130. J.C. Crockett, D.J. Mellis, D.I. Scott, M.H. Helfrich, New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. Osteoporos. Int. 22, 1-20 (2011)
131. N. Nakagawa, M. Kinosaki, K. Yamaguchi, N. Shima, H. Yasuda, K. Yano, T. Morinaga, K. Higashio, RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253, 395-400 (1998)
132. V. Kartsogiannis, H. Zhou, N.J. Horwood, R.J. Thomas, D.K. Hards, J.M. Quinn, P. Niforas, K.W. Ng, T.J. Martin, M.T. Gillespie, Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 25, 525-534 (1999)
133. R. Hanada, A. Leibbrandt, T. Hanada, S. Kitaoka, T. Furuyashiki, H. Fujihara, J. Trichereau, M. Paolino, F. Qadri, R. Plehm, S. Klaere, V. Komnenovic, H. Mimata, H. Yoshimatsu, N. Takahashi, A. von Haeseler, M. Bader, S.S. Kilic, Y. Ueta, C. Pifl, S. Narumiya, J.M. Penninger, Central control of fever and female body temperature by RANKL/RANK. Nature 462, 505-509 (2009)
134. K. Loser, A. Mehling, S. Loeser, J. Apelt, A. Kuhn, S. Grabbe, T. Schwarz, J.M. Penninger, S. Beissert, Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat. Med. 12, 1372-1379 (2006)
135. N.B. Watts, C. Roux, J.F. Modlin, J.P. Brown, A. Daniels, S. Jackson, S. Smith, D.J. Zack, L. Zhou, A. Grauer, S. Ferrari, Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos. Int. 23(1), 327-337 (2012)